Iterum Announces the appointment of Jeff Schaffnit as Chief Commercial Officer Industry Veteran To Lead Commercialization of Potential New Oral and IV Antibiotic DUBLIN and CHICAGO, Feb. 20, 2018 /PRNewswire/ — Iterum Therapeutics Limited, a clinical-stage...
Kyruus Joins the Epic App Orchard with Direct Scheduling Solution Integration Brings ProviderMatch DirectBook Capabilities to Epic Customers Boston, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that it has...
Kyruus Reports Record-Breaking Success in 2017 with Almost 400 Hospitals Across the U.S. Now on the ProviderMatch Platform Company Doubles Revenue Amid Rapidly Growing Demand for Enterprise-Wide Patient Access Solutions Boston, MA – Kyruus, a leader in provider...
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers Symposium Data show complete degradation of androgen receptor in models of enzalutamide-resistant prostate cancer NEW HAVEN, CT, February 9, 2018 –...
Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates $830 million in upfront and potential milestone payments to Arvinas across multiple PROTAC programs NEW HAVEN, CT.,...
Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study) – Pivotal Study to Evaluate the pan-KIT and PDGFRα inhibitor, DCC-2618, in Heavily Pretreated Patients with...
Recent Comments